Zeng J, Sun F, Wan J, Feng J, Li Y
Curr Opin Biomed Eng. 2024; 12:68-74.
PMID: 39651402
PMC: 11623207.
DOI: 10.1016/j.cobme.2019.09.010.
Gobbi G
J Psychiatry Neurosci. 2024; 49(5):E301-E318.
PMID: 39299781
PMC: 11426389.
DOI: 10.1503/jpn.240037.
Desire G, Simplice F, Guillaume C, Kamal F, Parfait B, Hermann T
Brain Sci. 2023; 13(11).
PMID: 38002521
PMC: 10670073.
DOI: 10.3390/brainsci13111561.
Sharp T, Collins H
Curr Top Behav Neurosci. 2023; 66:21-47.
PMID: 37955823
DOI: 10.1007/7854_2023_452.
Luo Q, Kanen J, Bari A, Skandali N, Langley C, Knudsen G
Neuropsychopharmacology. 2023; 49(3):600-608.
PMID: 37914893
PMC: 10789782.
DOI: 10.1038/s41386-023-01762-6.
Use of Fluoxetine to Augment the Inter-Ictal Hypercapnic Ventilatory Response in Patients with Epilepsy: A Pilot Study.
Sainju R, Dragon D, Winnike H, Ten Eyck P, Granner M, Gehlbach B
Neurol India. 2022; 70(5):2125-2129.
PMID: 36352620
PMC: 10234457.
DOI: 10.4103/0028-3886.359160.
Participation of the Serotonergic System and Brain-Derived Neurotrophic Factor in the Antidepressant-like Effect of Flavonoids.
German-Ponciano L, Rosas-Sanchez G, Cueto-Escobedo J, Fernandez-Demeneghi R, Guillen-Ruiz G, Soria-Fregozo C
Int J Mol Sci. 2022; 23(18).
PMID: 36142808
PMC: 9505567.
DOI: 10.3390/ijms231810896.
Occlusal Disharmony-A Potential Factor Promoting Depression in a Rat Model.
Zhang S, Wu L, Zhang M, He K, Wang X, Lin Y
Brain Sci. 2022; 12(6).
PMID: 35741632
PMC: 9221239.
DOI: 10.3390/brainsci12060747.
Natural Products for the Treatment of Post-stroke Depression.
Fang C, Zhang Z, Xu H, Liu Y, Wang X, Yuan L
Front Pharmacol. 2022; 13:918531.
PMID: 35712727
PMC: 9196125.
DOI: 10.3389/fphar.2022.918531.
Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline.
De Gregorio D, Inserra A, Enns J, Markopoulos A, Pileggi M, El Rahimy Y
Neuropsychopharmacology. 2022; 47(6):1188-1198.
PMID: 35301424
PMC: 9018770.
DOI: 10.1038/s41386-022-01301-9.
Galanin (1-15) Enhances the Behavioral Effects of Fluoxetine in the Olfactory Bulbectomy Rat, Suggesting a New Augmentation Strategy in Depression.
Flores-Burgess A, Millon C, Gago B, Garcia-Duran L, Cantero-Garcia N, Puigcerver A
Int J Neuropsychopharmacol. 2021; 25(4):307-318.
PMID: 34891163
PMC: 9017770.
DOI: 10.1093/ijnp/pyab089.
Astroglial Serotonin Receptors as the Central Target of Classic Antidepressants.
Verkhratsky A, Parpura V, Scuderi C, Li B
Adv Neurobiol. 2021; 26:317-347.
PMID: 34888840
PMC: 9015684.
DOI: 10.1007/978-3-030-77375-5_13.
5-HT Receptors and the Development of New Antidepressants.
Slifirski G, Krol M, Turlo J
Int J Mol Sci. 2021; 22(16).
PMID: 34445721
PMC: 8396477.
DOI: 10.3390/ijms22169015.
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
Galvao-Coelho N, Marx W, Gonzalez M, Sinclair J, De Manincor M, Perkins D
Psychopharmacology (Berl). 2021; 238(2):341-354.
PMID: 33427944
PMC: 7826317.
DOI: 10.1007/s00213-020-05719-1.
Discovery of Novel Indolealkylpiperazine Derivatives as Potent 5-HT Receptor Agonists for the Potential Future Treatment of Depression.
Zhu C, Li X, Peng W, Fu W
Molecules. 2020; 25(21).
PMID: 33139658
PMC: 7662226.
DOI: 10.3390/molecules25215078.
Pharmacological Treatment of Anxiety Disorders: The Role of the HPA Axis.
Tafet G, Nemeroff C
Front Psychiatry. 2020; 11:443.
PMID: 32499732
PMC: 7243209.
DOI: 10.3389/fpsyt.2020.00443.
Dual inhibitory action of trazodone on dorsal raphe serotonergic neurons through 5-HT1A receptor partial agonism and α1-adrenoceptor antagonism.
Montalbano A, Mlinar B, Bonfiglio F, Polenzani L, Magnani M, Corradetti R
PLoS One. 2019; 14(9):e0222855.
PMID: 31557210
PMC: 6763016.
DOI: 10.1371/journal.pone.0222855.
Protective Effects of 5-HT1A Receptor Inhibition and 5-HT2A Receptor Stimulation Against Streptozotocin-Induced Apoptosis in the Hippocampus.
Shahidi S, Hashemi-Firouzi N, Afshar S, Asl S, Komaki A
Malays J Med Sci. 2019; 26(2):40-51.
PMID: 31447607
PMC: 6687217.
DOI: 10.21315/mjms2019.26.2.5.
Targeting Serotonin1A Receptors for Treating Chronic Pain and Depression.
Haleem D
Curr Neuropharmacol. 2019; 17(12):1098-1108.
PMID: 31418663
PMC: 7057205.
DOI: 10.2174/1570159X17666190811161807.
Dysfunction in Serotonergic and Noradrenergic Systems and Somatic Symptoms in Psychiatric Disorders.
Liu Y, Zhao J, Fan X, Guo W
Front Psychiatry. 2019; 10:286.
PMID: 31178761
PMC: 6537908.
DOI: 10.3389/fpsyt.2019.00286.